A healthy investment in healthier futures.
Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.
Cryo-Cell Reports First Quarter 2013 Results - 4/5/2013
OLDSMAR, Fla. – April 5, 2013 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the first quarter ended February 28, 2013.
“I am pleased to report Cryo-Cell’s first quarter results, and in particular, cash flow from operations of slightly more than $500,000, which we believe indicates that the Cryo-Cell turnaround is well underway,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO. “Key metrics of performance such as the increase in revenues and the number of specimens processed of 10% and 12%, respectively, during the first quarter of fiscal 2013 as compared to the first quarter of fiscal 2012 are encouraging.”
Mark Portnoy, Cryo-Cell’s Co-CEO, added, “It is gratifying to see the progress the Company has made over the last year although we are still dealing with a variety of legacy issues. With the continued execution of the new sales and marketing initiatives, I expect to see further increases in revenue and earnings.”
Cryo-Cell Reports Financial Results For Fiscal 2012 - 3/1/2013
OLDSMAR, Fla. (February 28, 2013) – (OTC: CCEL) Cryo-Cell International, Inc., the world’s first private cord blood bank to separate and store stem cells, today announced results for its fiscal year 2012.
“Cryo-Cell fiscal 2012 financial results mask the significant structural improvements that have been achieved and reflect upon the company’s past rather than its future,” stated David Portnoy, Chairman and Co-CEO. “We look forward to enjoying the first fruits in fiscal 2013 from the many investments that have been made since the current Board of Directors was elected in August 2011.”
Co-CEO Mark Portnoy added, “The loss in 2012 was largely a result of one-time charges totaling $4.5 million, of which approximately $2.9 million were non-cash. In fact, net cash provided by operations in 2012 was a positive $361,000. Cryo-Cell made great strides during fiscal 2012 repositioning itself in the marketplace and is now able to build on to the base it has established.”
Cryo-Cell International has the Lowest Beta in the Health Care Services Industry (CCEL, MZEI, AMS, CO, SMED) - 11/13/2012
Below are the three companies in the Health Care Services industry with the lowest betas. Lower-beta stocks mean minimal volatility and are therefore generally considered to be a less risk and offer more stable returns.
Cryo-Cell International ranks lowest with a a beta of 0.1. Following is Medizone International with a beta of 0.1. American Shared Hospital Services ranks third lowest with a beta of 0.3.
China Cord Blood follows with a beta of 0.4, and Sharps Compliance rounds out the bottom five with a beta of 0.5.
SmarTrend recommended that subscribers consider buying shares of Sharps Compliance on October 17th, 2012 as our technology indicated a new Uptrend was in progress when shares hit $2.90. Since that recommendation, shares of Sharps Compliance have risen 9.2%. We continue to monitor Sharps Compliance for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.